5 In its application for an extension of the term of the Patent, Lilly relied upon registrations on the Australian Register of Therapeutic Goods (ARTG) for the commercial product Gemcitabine hydrochloride. At the time InterPharma became aware of the [extension] Decision on 2 August 2007, it had not applied for Pharmaceutical Benefits Scheme (PBS) listing of Gemcitabine EBEWE. The second is whether the applicant has standing to claim relief under the ADJR Act, s 192 of the Patents Act and s 39B of the Judiciary Act . Interpharma Pty Ltd v Commissioner of Patents [2008] FCA 1283 (21 August 2008)